Baseimmune and researchers from Imperial College announce co-development of a multi-gene malaria vaccine
Baseimmune is combining forces with the laboratory of Professor Jake Baum at Imperial College London to test a multi-target vaccine against Malaria to improve efficacy and facilitate application in the field.
Malaria disease is responsible for 0.5 million deaths each year and has a staggering impact on the health and economic well-being of low to middle income countries (LMICs) globally1.
The disease is caused by a complex parasite with more than 5000 genes, each with distinct protein expression throughout the stages of its lifecycle. Baseimmune’s platform designed an artificial protein with regions from over 40 proteins designed to prevent infection and stop disease, with a simple two dose immunisation regimen.
Baseimmune is a data-driven vaccine design platform focused on antigen discovery and vaccine development. The technology is based on a bespoke deep-learning platform harnessing recent developments in biomedical and “OMICS’ big data used to inform antigen design. The company is the result of years of computational, laboratory and clinical research combined with leading experience in vaccine formulation and production.
About the Baum Lab
The Baum lab has a wide range of interests covering every scale of biology and every stage of the malaria parasite lifecycle, developing new innovative technologies that advance the malaria eradication agenda. Over time, a key feature of our work has been imaging, visualising parasite biology at every scale from atomic to single molecule and sub-cellular super resolution right through to live imaging of malaria parasites on the move in multi-colour 4D. Beyond microscopy, however, we are also keen geneticists, using CRISPR/Cas9 tech, and increasingly fascinated by immunology, flow cytometry and vaccine technology. Our interests depend on the full mosquito lifecycle (using Plasmodium berghei and P. falciparum) and development of robust methods for host cell invasion study, whether red blood cell or hepatocyte. Together with international collaborators we're also heavily invested in applying biological knowledge to diagnostics. However, in the last five years our primary focus has shifted to walking the walk of next generation malaria vaccine technology.
“We believe that the complex analysis of big omics data to rationally design safe and effective vaccines will be Baseimmune’s biggest contribution to society and we hope to be a resource in the event of potential public health crises”
Find out more about us: Who are we?
Follow Us @baseimmune
PARTNER ∙ ACCELERATOR ∙ SCIENCE
© 2023 Baseimmune. All rights reserved
London BioScience Innovation Centre, 2 Royal College Street, London, NW1 0NH
Designed and created with love by the Baseimmune Team ♥︎